Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea, Switzerland Ink MOU To Combine Talents In Pharma, Medical Devices

This article was originally published in PharmAsia News

Executive Summary

In a bid to bolster their respective health care industries, South Korea and Switzerland signed an MOU to cooperate on life sciences investments by combining Switzerland’s knowhow in precision machinery, nanotechnology and biotechnology with Korea’s expertise in manufacturing technology.

You may also be interested in...

Novartis Signs MOU To Invest $100 Million In R&D, Exchanges With Korean Scientists By 2013

SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose

Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts